Influenza Vaccine Feasibility Study in Children With Persistent Asthma

Completed · Phase 4

Conditions studied: Asthmatic

In brief

This study is designed to note whether a larger safety study using quadrivalent live attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated influenza vaccine (IIV4)(FLUARIX®), would be feasible in children with persistent asthma. Half of the patients in this study will receive the FLUARIX® influenza vaccine, while the other half will receive a cell cultured quadrivalent inactivated influenza vaccine (ccIIV4)(Flucelvax®) being used as a surrogate for LAIV4.

Key facts

Study ID

NCT02967393

Run by

Vanderbilt University Medical Center

People needed

40

Starts

2016-10-10

Expected to finish

2017-02-01

Last updated by the study team

2018-04-23

Who can join

Age: 5 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children between 5-11 years of age, inclusive, at enrollment.
• Participant must have a current diagnosis of persistent asthma.
• Parent/legal guardian must provide written informed consent and subject must provide assent as appropriate for age prior to initiation of study procedures and according to local Institutional Review Board (IRB) requirement.
• Parent/legal guardian and subject must be willing and able to comply with planned study procedures and be available for all study visits.
• Children aged 5-8 years must have received at least 2 doses of seasonal trivalent or quadrivalent influenza vaccine prior to the current influenza season. Children 9-11 years must have received at least 1 dose of seasonal trivalent or quadrivalent influenza vaccine prior to the current influenza season.
• Is in good health, other than their asthma, as determined by medical history and targeted physical examination based on medical history.
• English or Spanish literate.
• Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls and collection of information.

You may not qualify if…

• Acute illness and/or a reported oral temperature of ≥ 100.4°F within 72 hours prior to enrollment (this may result in a temporary delay of vaccination.
• Use of antipyretic medication during the preceding 24 hours that might mask a fever (temporary deferral).
• History of a severe allergic reaction (e.g., anaphylaxis) to any component of study influenza vaccines or a known allergy to eggs.
• Receipt of any licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to vaccination or planned receipt of any licensed vaccine within 42 days after vaccination.
• Receipt of current year's licensed influenza vaccine.
• Received an investigational agent (licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication) in the 28 days prior to enrollment or planned receipt before 42 days after vaccination.
• Has immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months.
• Has taken ≥ 20mg/day of prednisone or its equivalent, for 14 days or more within the past 28 days.
• Has know active neoplasm or a history of any hematologic malignancy.
• Has had a previous exacerbation of their asthma symptoms requiring systemic steroids within the prior 28 days, or has had a life-threatening exacerbation of asthma in the past two years (e.g. hypoxic seizure, mechanical ventilation).
• History of Guillian-Barre syndrome within 6 weeks of previous influenza vaccination.
• Has any condition that, in the opinion of the investigator, would interfere with the evaluation of the responses or would place the participant at unacceptable risk of injury.
• Has any diagnosis, current or past, of schizophrenia, bipolar disease, or other major psychiatric disorder.
• Currently taking aspirin or aspirin-containing products.

Where it is running

• Centers for Disease Control and Prevention — Atlanta, Georgia, United States
• Duke Clinical Vaccine Unit — Durham, North Carolina, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
• Vanderbilt Vaccine Research Program — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.